- Markets
- Healthcare
- SAMRATPH
SAMRATPH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Upcoming Events:
Quarterly Results
Events:
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Samrat Pharmachem do?
Samrat Pharmachem Ltd specializes in manufacturing iodine salts & bromine salts used in various industries such as Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc.
Who are the competitors of Samrat Pharmachem?
Samrat Pharmachem major competitors are Source Natural Foods, Bharat Immunological, Parnax Lab, Mercury Laboratories, Murae Organisor, Onyx Biotec, Lasa Supergenerics. Market Cap of Samrat Pharmachem is ₹125 Crs. While the median market cap of its peers are ₹106 Crs.
Is Samrat Pharmachem financially stable compared to its competitors?
Samrat Pharmachem seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Samrat Pharmachem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Samrat Pharmachem latest dividend payout ratio is 14.29% and 3yr average dividend payout ratio is 5.98%
How has Samrat Pharmachem allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Samrat Pharmachem balance sheet?
Balance sheet of Samrat Pharmachem is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Samrat Pharmachem improving?
The profit is oscillating. The profit of Samrat Pharmachem is ₹8.91 Crs for TTM, ₹2.16 Crs for Mar 2024 and ₹16.63 Crs for Mar 2023.
Is the debt of Samrat Pharmachem increasing or decreasing?
Yes, The debt of Samrat Pharmachem is increasing. Latest debt of Samrat Pharmachem is ₹2.25 Crs as of Sep-24. This is greater than Mar-24 when it was -₹10.95 Crs.
Is Samrat Pharmachem stock expensive?
Samrat Pharmachem is not expensive. Latest PE of Samrat Pharmachem is 14.06, while 3 year average PE is 17.46. Also latest EV/EBITDA of Samrat Pharmachem is 11.1 while 3yr average is 25.31.
Has the share price of Samrat Pharmachem grown faster than its competition?
Samrat Pharmachem has given better returns compared to its competitors. Samrat Pharmachem has grown at ~41.21% over the last 5yrs while peers have grown at a median rate of 16.0%
Is the promoter bullish about Samrat Pharmachem?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Samrat Pharmachem is 49.09% and last quarter promoter holding is 49.09%.
Are mutual funds buying/selling Samrat Pharmachem?
There is Insufficient data to gauge this.